Retrospective analysis of palliative chemotherapy for the patients with bladder adenocarcinoma

Korean cancer study group genitourinary and gynecology cancer committee

Moon Jin Kim, Young Sam Kim, Sung Yong Oh, Suee Lee, Young Jin Choi, Young Mi Seol, Min Jae Park, Ki Hyang Kim, Lee Chun Park, Jung Hun Kang, In Gyu Hwang, Soon Il Lee, Seung Taek Lim, Hyo Song Kim, Ho Yeong Lim, SunYoung Rha, Hyo Jin Kim

Research output: Contribution to journalArticle

Abstract

Background/Aims: Because of rarity, role of chemotherapy of bladder adenocarcinoma are still unidentified. Therefore, we performed a retrospective analysis of the clinical features and chemotherapy outcomes of bladder adenocarcinoma. Methods: Eligible patients for this retrospective analysis were initially diagnosed with bladder adenocarcinoma and presented with a clinically no other primary site of origin. The collected data included age, gender, performance status, stage, hemoglobin, albumin, initial date of diagnosis, treatment modality utilized, response to treatment, presence of relapse, last status of patient, and last date of follow-up. Results: We retrospectively reviewed 29 patients, who were treated with chemotherapy for bladder adenocarcinoma at 10 Korean medical institutions from 2004 to 2014. The median age of patients was 58 years (range, 17 to 78) and 51.7% of the patients were female. Urachal adenocarcinoma was identified in 15 patients. Of 27 symptomatic patients, 22 experienced gross hematuria. Twelve patients were treated with 5-f luorouracil based chemotherapy, five were gemcitabine based, three were taxane and others. Thirteen of them achieved complete response (10.3%) or partial response (34.5%). Median progression-free survival (PFS) and overall survival (OS) for all patients were 10.6 months (95% confidence interval [CI], 9.5 to 11.6) and 24.5 months (95% CI, 1.2 to 47.8), respectively. The cases of urachal adenocarcinoma exhibited worse tendency in PFS and OS (p = 0.024 and p = 0.046, respectively). Conclusions: Even though bladder adenocarcinoma had been observed moderate effectiveness to chemotherapy, bladder adenocarcinoma is a highly aggressive form of bladder cancer. PFS and OS were short especially in urachal carcinoma.

Original languageEnglish
Pages (from-to)383-390
Number of pages8
JournalKorean Journal of Internal Medicine
Volume33
Issue number2
DOIs
Publication statusPublished - 2018 Mar 1

Fingerprint

Urogenital Neoplasms
Gynecology
Urinary Bladder
Adenocarcinoma
Drug Therapy
Neoplasms
Disease-Free Survival
gemcitabine
Survival
Confidence Intervals
Hematuria
Urinary Bladder Neoplasms
Albumins
Hemoglobins

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Cite this

Kim, Moon Jin ; Kim, Young Sam ; Oh, Sung Yong ; Lee, Suee ; Choi, Young Jin ; Seol, Young Mi ; Park, Min Jae ; Kim, Ki Hyang ; Park, Lee Chun ; Kang, Jung Hun ; Hwang, In Gyu ; Lee, Soon Il ; Lim, Seung Taek ; Kim, Hyo Song ; Lim, Ho Yeong ; Rha, SunYoung ; Kim, Hyo Jin. / Retrospective analysis of palliative chemotherapy for the patients with bladder adenocarcinoma : Korean cancer study group genitourinary and gynecology cancer committee. In: Korean Journal of Internal Medicine. 2018 ; Vol. 33, No. 2. pp. 383-390.
@article{4c660a5e9a3a48cc90894b901be91ee1,
title = "Retrospective analysis of palliative chemotherapy for the patients with bladder adenocarcinoma: Korean cancer study group genitourinary and gynecology cancer committee",
abstract = "Background/Aims: Because of rarity, role of chemotherapy of bladder adenocarcinoma are still unidentified. Therefore, we performed a retrospective analysis of the clinical features and chemotherapy outcomes of bladder adenocarcinoma. Methods: Eligible patients for this retrospective analysis were initially diagnosed with bladder adenocarcinoma and presented with a clinically no other primary site of origin. The collected data included age, gender, performance status, stage, hemoglobin, albumin, initial date of diagnosis, treatment modality utilized, response to treatment, presence of relapse, last status of patient, and last date of follow-up. Results: We retrospectively reviewed 29 patients, who were treated with chemotherapy for bladder adenocarcinoma at 10 Korean medical institutions from 2004 to 2014. The median age of patients was 58 years (range, 17 to 78) and 51.7{\%} of the patients were female. Urachal adenocarcinoma was identified in 15 patients. Of 27 symptomatic patients, 22 experienced gross hematuria. Twelve patients were treated with 5-f luorouracil based chemotherapy, five were gemcitabine based, three were taxane and others. Thirteen of them achieved complete response (10.3{\%}) or partial response (34.5{\%}). Median progression-free survival (PFS) and overall survival (OS) for all patients were 10.6 months (95{\%} confidence interval [CI], 9.5 to 11.6) and 24.5 months (95{\%} CI, 1.2 to 47.8), respectively. The cases of urachal adenocarcinoma exhibited worse tendency in PFS and OS (p = 0.024 and p = 0.046, respectively). Conclusions: Even though bladder adenocarcinoma had been observed moderate effectiveness to chemotherapy, bladder adenocarcinoma is a highly aggressive form of bladder cancer. PFS and OS were short especially in urachal carcinoma.",
author = "Kim, {Moon Jin} and Kim, {Young Sam} and Oh, {Sung Yong} and Suee Lee and Choi, {Young Jin} and Seol, {Young Mi} and Park, {Min Jae} and Kim, {Ki Hyang} and Park, {Lee Chun} and Kang, {Jung Hun} and Hwang, {In Gyu} and Lee, {Soon Il} and Lim, {Seung Taek} and Kim, {Hyo Song} and Lim, {Ho Yeong} and SunYoung Rha and Kim, {Hyo Jin}",
year = "2018",
month = "3",
day = "1",
doi = "10.3904/kjim.2015.162",
language = "English",
volume = "33",
pages = "383--390",
journal = "Korean Journal of Internal Medicine",
issn = "1226-3303",
publisher = "Korean Association of Internal Medicine",
number = "2",

}

Kim, MJ, Kim, YS, Oh, SY, Lee, S, Choi, YJ, Seol, YM, Park, MJ, Kim, KH, Park, LC, Kang, JH, Hwang, IG, Lee, SI, Lim, ST, Kim, HS, Lim, HY, Rha, S & Kim, HJ 2018, 'Retrospective analysis of palliative chemotherapy for the patients with bladder adenocarcinoma: Korean cancer study group genitourinary and gynecology cancer committee', Korean Journal of Internal Medicine, vol. 33, no. 2, pp. 383-390. https://doi.org/10.3904/kjim.2015.162

Retrospective analysis of palliative chemotherapy for the patients with bladder adenocarcinoma : Korean cancer study group genitourinary and gynecology cancer committee. / Kim, Moon Jin; Kim, Young Sam; Oh, Sung Yong; Lee, Suee; Choi, Young Jin; Seol, Young Mi; Park, Min Jae; Kim, Ki Hyang; Park, Lee Chun; Kang, Jung Hun; Hwang, In Gyu; Lee, Soon Il; Lim, Seung Taek; Kim, Hyo Song; Lim, Ho Yeong; Rha, SunYoung; Kim, Hyo Jin.

In: Korean Journal of Internal Medicine, Vol. 33, No. 2, 01.03.2018, p. 383-390.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Retrospective analysis of palliative chemotherapy for the patients with bladder adenocarcinoma

T2 - Korean cancer study group genitourinary and gynecology cancer committee

AU - Kim, Moon Jin

AU - Kim, Young Sam

AU - Oh, Sung Yong

AU - Lee, Suee

AU - Choi, Young Jin

AU - Seol, Young Mi

AU - Park, Min Jae

AU - Kim, Ki Hyang

AU - Park, Lee Chun

AU - Kang, Jung Hun

AU - Hwang, In Gyu

AU - Lee, Soon Il

AU - Lim, Seung Taek

AU - Kim, Hyo Song

AU - Lim, Ho Yeong

AU - Rha, SunYoung

AU - Kim, Hyo Jin

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Background/Aims: Because of rarity, role of chemotherapy of bladder adenocarcinoma are still unidentified. Therefore, we performed a retrospective analysis of the clinical features and chemotherapy outcomes of bladder adenocarcinoma. Methods: Eligible patients for this retrospective analysis were initially diagnosed with bladder adenocarcinoma and presented with a clinically no other primary site of origin. The collected data included age, gender, performance status, stage, hemoglobin, albumin, initial date of diagnosis, treatment modality utilized, response to treatment, presence of relapse, last status of patient, and last date of follow-up. Results: We retrospectively reviewed 29 patients, who were treated with chemotherapy for bladder adenocarcinoma at 10 Korean medical institutions from 2004 to 2014. The median age of patients was 58 years (range, 17 to 78) and 51.7% of the patients were female. Urachal adenocarcinoma was identified in 15 patients. Of 27 symptomatic patients, 22 experienced gross hematuria. Twelve patients were treated with 5-f luorouracil based chemotherapy, five were gemcitabine based, three were taxane and others. Thirteen of them achieved complete response (10.3%) or partial response (34.5%). Median progression-free survival (PFS) and overall survival (OS) for all patients were 10.6 months (95% confidence interval [CI], 9.5 to 11.6) and 24.5 months (95% CI, 1.2 to 47.8), respectively. The cases of urachal adenocarcinoma exhibited worse tendency in PFS and OS (p = 0.024 and p = 0.046, respectively). Conclusions: Even though bladder adenocarcinoma had been observed moderate effectiveness to chemotherapy, bladder adenocarcinoma is a highly aggressive form of bladder cancer. PFS and OS were short especially in urachal carcinoma.

AB - Background/Aims: Because of rarity, role of chemotherapy of bladder adenocarcinoma are still unidentified. Therefore, we performed a retrospective analysis of the clinical features and chemotherapy outcomes of bladder adenocarcinoma. Methods: Eligible patients for this retrospective analysis were initially diagnosed with bladder adenocarcinoma and presented with a clinically no other primary site of origin. The collected data included age, gender, performance status, stage, hemoglobin, albumin, initial date of diagnosis, treatment modality utilized, response to treatment, presence of relapse, last status of patient, and last date of follow-up. Results: We retrospectively reviewed 29 patients, who were treated with chemotherapy for bladder adenocarcinoma at 10 Korean medical institutions from 2004 to 2014. The median age of patients was 58 years (range, 17 to 78) and 51.7% of the patients were female. Urachal adenocarcinoma was identified in 15 patients. Of 27 symptomatic patients, 22 experienced gross hematuria. Twelve patients were treated with 5-f luorouracil based chemotherapy, five were gemcitabine based, three were taxane and others. Thirteen of them achieved complete response (10.3%) or partial response (34.5%). Median progression-free survival (PFS) and overall survival (OS) for all patients were 10.6 months (95% confidence interval [CI], 9.5 to 11.6) and 24.5 months (95% CI, 1.2 to 47.8), respectively. The cases of urachal adenocarcinoma exhibited worse tendency in PFS and OS (p = 0.024 and p = 0.046, respectively). Conclusions: Even though bladder adenocarcinoma had been observed moderate effectiveness to chemotherapy, bladder adenocarcinoma is a highly aggressive form of bladder cancer. PFS and OS were short especially in urachal carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=85043522187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043522187&partnerID=8YFLogxK

U2 - 10.3904/kjim.2015.162

DO - 10.3904/kjim.2015.162

M3 - Article

VL - 33

SP - 383

EP - 390

JO - Korean Journal of Internal Medicine

JF - Korean Journal of Internal Medicine

SN - 1226-3303

IS - 2

ER -